Boston Scientific (NYSE:BSX) Releases Q1 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its first quarter 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.780-0.800 for the period, compared to the consensus estimate of 0.790. The company issued revenue guidance of $5.1 billion-$5.2 billion, compared to the consensus revenue estimate of $5.2 billion. Boston Scientific also updated its FY 2026 guidance to 3.430-3.490 EPS.

Boston Scientific Stock Down 15.4%

Boston Scientific stock traded down $14.14 during trading on Wednesday, reaching $77.48. The stock had a trading volume of 34,552,151 shares, compared to its average volume of 13,667,540. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific has a 52-week low of $75.00 and a 52-week high of $109.50. The stock has a market cap of $114.85 billion, a PE ratio of 41.42, a P/E/G ratio of 1.63 and a beta of 0.67. The business has a 50 day moving average price of $94.89 and a 200 day moving average price of $99.29.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company’s revenue was up 15.9% on a year-over-year basis. During the same period last year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts predict that Boston Scientific will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on BSX. Barclays lowered their price objective on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research report on Tuesday. Oppenheimer decreased their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. Needham & Company LLC reaffirmed a “buy” rating on shares of Boston Scientific in a report on Thursday, January 15th. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Finally, Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $123.26.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 191,105 shares of company stock worth $18,067,697 in the last 90 days. 0.50% of the stock is owned by insiders.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat: BSX posted $0.80 EPS vs. $0.78 consensus and reported 15.9% year-over-year net sales growth — confirms underlying demand and operational momentum. Zacks: Boston Scientific Beats Q4
• Positive Sentiment: Revenue detail: net sales ~$5.29B with ~12.7% organic growth — supports medium-term revenue base and validates product momentum across several franchises. PR Newswire: Q4 Results
• Neutral Sentiment: Analyst backdrop: many firms still rate BSX a Buy with mid- to high‑teens upside targets — consensus remains constructive despite near-term headwinds. MarketBeat: Analyst Consensus
• Negative Sentiment: Soft 2026 guidance: management issued modest revenue growth and profit guidance that trailed Street expectations, which was the primary driver of the early selloff. WSJ: Profit, Sales Rise but Issues Soft Guidance
• Negative Sentiment: Electrophysiology weakness: management called out light EP sales (one of its key growth drivers), raising near-term execution concerns. Blockonomi: Why Shares Dropped
• Negative Sentiment: Market positioning and sentiment: unusually large put-option buying (≈23,490 puts, ~52% above average) indicates elevated bearish hedging/speculation adding downward pressure.
• Negative Sentiment: Insider sale: CEO Michael Mahoney sold ~160,901 shares (~$15M) last week; such a large disclosed sale can amplify negative sentiment even if preplanned. SEC Filing: Insider Sale

Institutional Trading of Boston Scientific

Hedge funds have recently modified their holdings of the business. Brighton Jones LLC boosted its position in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the 2nd quarter valued at about $26,000. Main Street Financial Solutions LLC lifted its stake in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after purchasing an additional 1,971 shares during the period. Ieq Capital LLC boosted its holdings in Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after buying an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC grew its position in Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after buying an additional 2,556 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.